Akwahosan ho nimdeɛ a ɛfa ahrawa mu kokoram ho kyerɛ nsakrae a ɛba nipadua mu nneɛma mu ne akwan a ɛfa ahrawa mu kokoram ho.
Mframa mu kokoram yɛ yare a ɛsae esiane sɛ nkwammoaa a enni ahoɔden no nya nkɔanim na ɛpae wɔ ahrawa mu.
Saa nkwammoaa yi betumi ama yare no ayɛ kɛse na atrɛw akɔ nipadua no afã foforo, na ɛde nsɛnkyerɛnne ne ɔhaw ahorow ba.
Akwahosan ho nimdeɛ a ɛfa ahrawa mu kokoram ho no fa nneɛma pii ho, a ebi ne awosu mu nsakrae, nneɛma a atwa yɛn ho ahyia, ne asetena kwan a obi fa so.
Yareɛ a ɛde yare ba tumi kɔso wɔ DNA a ɛwɔ ahrawa mu, na ɛde yare ba a ɛntumi nsi ne kwan so.
Wobetumi anya saa nsakrae yi afi awo mu anaa obi anya bi, na ebetumi aba sɛ obi anya kokoram, te sɛ tawa wusiw, radon, asbestos, ne mframa a asɛe.
Wɔtumi kyekyɛ ahrawa mu kokoram mu ayɛ no akuw mmienu: nkwammoaa nketewa a ɛwɔ ahrawa mu kokoram (SCLC) ne nkwammoaa nketewa a enni ahrawa mu kokoram (NSCLC).
Abɔde a ɛma yare ba wɔ ahrawa mu kokoram yi mu betumi ayɛ soronko, efisɛ wɔwɔ awosu mu nsakrae soronko na wonnya ayaresa a ɛfata.
Pathophysiology of lung cancer nso fa sɛnea nkwammoaa a ɛwɔ kokoram mu ne nipadua a atwa ho ahyia di dwuma ho, a nea ɛka ho ne nipadua mu tumi a ɛko tia nyarewa.
Kokoram nkwammoaa betumi afa nipadua mu nkwaadɔm no ho, na ama wɔatumi anyin na wɔabɔ wɔn ho dawuru a obiara nsiw wɔn kwan.
Bio nso, kokoram mmoawa no betumi ama kokoram no anyin na atrɛw denam mmoa a wɔde ma kokoram nkwammoaa no so.
Akwahosan ho nimdeɛ a ɛfa ahrawa mu kokoram ho yɛ ade a ɛkyere adwene na ɛsakra, na nhwehwɛmufo reyɛ adwuma bere nyinaa de ate saa nneɛma no ase yiye na ama wɔanya ayaresa a etu mpɔn na ama ayarefo no anya nkɔso.
Li Z, Qian Y, Li W, Liu L, Yu L, Liu X, Wu G, Wang Y, Luo W, Fang F, Liu Y, Song F, Cai Z, Chen W, Huang W: Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience. 2020, 23 (8): 101411.
Nurwidya F, Syahruddin E, Yunus F: Pain management in lung cancer. Adv Respir Med. 2016, 84 (6): 331-336.
Khan KA, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT: Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung. 2015, 193 (1): 71-7.
Paramanantham A, Asfiya R, Das S, McCully G, Srivastava A: Extracellular Vesicle (EVs) Associated Non-Coding RNAs in Lung Cancer and Therapeutics. Int J Mol Sci. 2022, 23 (21): .
Lee D, Kim Y, Chung C: Scientific Validation and Clinical Application of Lung Cancer Organoids. Cells. 2021, 10 (11): .
Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C: Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment. Curr Pharm Des. 2016, 22 (14): 2160-9.
['Abɔdin: ayaresa']
['Wɔayɛ wɛbsaet yi sɛ wɔmfa nkyerɛkyerɛ na wɔnka ho asɛm kɛkɛ, na ɛnyɛ sɛ wɔde ayaresa ho afotu anaa adwumakuw bi mmoa rema.']
['Ɛnsɛ sɛ wɔde nsɛm a wɔde ama no di dwuma de hwehwɛ yare anaa yare bi ho ayaresa, na ɛsɛ sɛ wɔn a wɔrehwehwɛ ayaresa ho afotu no ne oduruyɛfo a ɔwɔ tumi krataa di nkitaho.']
['Yɛsrɛ wo hyɛ no nsow sɛ amemene no mu mfiri a ɛma nsɛmmisa ho mmuae no nyɛ pɛpɛɛpɛ bere a ɛfa akontaahyɛde ho no. Sɛ nhwɛso no, nnipa dodow a wɔanya yare pɔtee bi.']
["Hwehwɛ afotu fi wo dɔkota anaa ayaresafo a wɔfata hɔ bere biara wɔ yareɛ ho. Nnyae ayaresa ho afotuo a wɔn a wɔn ho akokwaw de ma no ho adwenemu anaa twentwɛn wo nan ase sɛ worebɛhwehwɛ esiane biribi a woakenkan wɔ wɛbsaet yi so nti. Sɛ ɛyɛ wo sɛ wowɔ yareɛ ho nsɛmmisa a, frɛ 911 anaa kɔ ayaresabea a ɛbɛn wo pɛɛ ntɛm ara. Saa wɛbsaet yi anaa dwuma a wode di no mma wonnya oduruyɛfo ne ɔyarefo ayɔnkofa biara. BioMedLib anaa n'adwumayɛfoɔ anaa obiara a ɔde ne ho bɔ wɛbsaet yi ho dawuro biara nni mu, a ɛkyerɛ anaa enni mu, fa nsɛm a wɔde ama wɔ ha anaa dwuma a wɔde di no ho."]
['Disclaimer: copyright']
["Digital Millennium Copyright Act a w'atwe no afe 1998 wɔ U.S. Mmara 17 § 512 (DMCA) no ma wɔn a w'wɔ tumi sɛ wɔtwe wɔn ho fi nneɛma a wɔde agu intanɛt so ho kwan."]
['Sɛ wogye di sɛ wo nsɛm anaa nneɛma bi a ɛwɔ yɛn wɛbsaet anaa yɛn dwumadie mu no to wo mmara a woahyehyɛ no so a, wo (anaa wo dwumadifoɔ) bɛtumi de nkaebɔ ama yɛn de apɛ sɛ yɛyi nsɛm anaa nneɛma no firi hɔ anaa yɛsi ho kwan.']
["Ɛsɛ sɛ wɔde nkaebɔ fa e-mail so kɔma wɔn (hwɛ 'Contact' section ma e-mail address)."]
['DMCA hwehwɛ sɛ wo dawurubɔ a ɛfa mmara a obi abu so ho no de nsɛm a edidi so yi ka ho: (1) nkyerɛwde a ɛkyerɛ adwuma a mmara bɔ ho ban a obi abu so no; (2) nsɛm a wɔkyerɛ sɛ obi abu so no ne ɛho nsɛm a ɛfata a ɛbɛma yɛahunu faako a saa nsɛm no wɔ; (3) wo nkitahodi ho nsɛm, a wo address, fon number ne email ka ho; (4) krataa a woakyerɛ sɛ wowɔ gyidie pa sɛ nea woabɔ ho dawuru no nni mmara no wura anaa nea ɔhwɛ so anaa mmara biara tumi mu.']
['(5) sɛ wo de wo nsa ahyɛ krataa ase, na wohyɛ sɛ wobedi atoro, sɛ nsɛm a ɛwɔ krataa no mu yɛ nokware, na wowɔ tumi sɛ wode wo nsa bɛka nneɛma a obi akyerɛw abrɛ wo ase no;']
["و (6) physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner's behalf."]
['Sɛ woantwerɛ nsɛm a ɛwɔ soro yi nyinaa amfiri wo nkrataa no mu a, ɛbɛtumi ama wo kyɛfa no akyɛ.']
['Nkitahodi']
['Yɛsrɛ wo, fa nsɛmmisa anaa nyansahyɛ biara fa e-mail so brɛ yɛn.']
What is pathophysiology of lung cancer?
The pathophysiology of lung cancer refers to the changes in the normal physiological processes and mechanisms that occur in the development and progression of lung cancer.
Lung cancer is a complex disease that arises from the uncontrolled growth and division of abnormal cells in the lungs.
These cells can form tumors and spread to other parts of the body, leading to various symptoms and complications.
The pathophysiology of lung cancer involves several factors, including genetic mutations, environmental factors, and lifestyle choices.
Genetic mutations can occur in the DNA of lung cells, leading to uncontrolled cell growth and division.
These mutations can be inherited or acquired, and they can be caused by exposure to carcinogens, such as tobacco smoke, radon, asbestos, and air pollution.
Lung cancer can be classified into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into three subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
The pathophysiology of these types of lung cancer can differ, as they have different genetic mutations and respond differently to treatment.
The pathophysiology of lung cancer also involves the interaction between cancer cells and the surrounding tissue, including the immune system.
Cancer cells can evade the immune system, allowing them to grow and spread unchecked.
Additionally, the tumor microenvironment can promote tumor growth and metastasis by providing a supportive environment for cancer cells.
The pathophysiology of lung cancer is a complex and dynamic process, and researchers are continuously working to better understand the underlying mechanisms to develop more effective treatments and improve patient outcomes.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Ɛfa ho']
['BioMedLib de kɔmputa a ɛyɛ adwuma ankasa (fidie a wɔde sua ade) na ɛyɛ nsɛmmisa ne mmuae.']
['Yɛde yɛn afi ayaresa ho nhoma ɔpepem 35 a ɛwɔ PubMed/Medline ase. Afei nso, RefinedWeb wɛb nkratafa.']
